CU24701B1 - Composiciones de vacuna estables que comprenden inter alia un flavivirus recombinante vivo atenuado y proceso para la preparación de las mismas - Google Patents

Composiciones de vacuna estables que comprenden inter alia un flavivirus recombinante vivo atenuado y proceso para la preparación de las mismas

Info

Publication number
CU24701B1
CU24701B1 CU2020000036A CU20200036A CU24701B1 CU 24701 B1 CU24701 B1 CU 24701B1 CU 2020000036 A CU2020000036 A CU 2020000036A CU 20200036 A CU20200036 A CU 20200036A CU 24701 B1 CU24701 B1 CU 24701B1
Authority
CU
Cuba
Prior art keywords
live attenuated
preparation
inter alia
vaccine compositions
attenuated recombinant
Prior art date
Application number
CU2020000036A
Other languages
English (en)
Other versions
CU20200036A7 (es
Inventor
Sandeep Dinkar Baraskar
Rajeev Mhalasakant Dhere
Shashikant Janardan Ghodekar
Vinit Kumar
Rajeev Mehla
Rohit Bapurav Sonar
Leena Ravindra Yeolekar
Original Assignee
Serum Institute Of India Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serum Institute Of India Pvt Ltd filed Critical Serum Institute Of India Pvt Ltd
Publication of CU20200036A7 publication Critical patent/CU20200036A7/es
Publication of CU24701B1 publication Critical patent/CU24701B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/06—Inactivation or attenuation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

<p>Composiciones inmunogénicas liofilizadas estables que comprenden, entre otros, flavivirus vivos atenuados recombinantes, más preferiblemente virus del dengue recombinantes vivos atenuados, al menos un hidrato de carbono, al menos un aminoácido, y que son particularmente susceptibles de tratamientos de liofilización rápida en donde, la composición conserva las características deseadas de un virus, que incluye la viabilidad, inmunogenicidad y estabilidad del virus. La mencionada composición inmunogénica está libre de conservantes, polímeros y surfactantes. Los métodos para fabricar las mencionadas composiciones inmunogénicas liofilizadas estables. </p>
CU2020000036A 2017-10-16 2018-10-10 Composiciones de vacuna estables que comprenden inter alia un flavivirus recombinante vivo atenuado y proceso para la preparación de las mismas CU24701B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201721036696 2017-10-16
PCT/IN2018/050645 WO2019077622A1 (en) 2017-10-16 2018-10-10 STABLE VACCINE COMPOSITIONS COMPRISING, BOTH, A LIVING RECOMBINANT FLAVIVUS ATTENUATED AND PROCESS FOR PREPARING THE SAME

Publications (2)

Publication Number Publication Date
CU20200036A7 CU20200036A7 (es) 2021-03-11
CU24701B1 true CU24701B1 (es) 2024-04-08

Family

ID=66173564

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2020000036A CU24701B1 (es) 2017-10-16 2018-10-10 Composiciones de vacuna estables que comprenden inter alia un flavivirus recombinante vivo atenuado y proceso para la preparación de las mismas

Country Status (22)

Country Link
US (1) US11660333B2 (es)
EP (1) EP3697897A4 (es)
JP (1) JP7261239B2 (es)
KR (1) KR20200088326A (es)
CN (1) CN111655844B (es)
AR (1) AR114138A1 (es)
AU (1) AU2018352447A1 (es)
BR (1) BR112020007513A2 (es)
CA (1) CA3079151A1 (es)
CO (1) CO2020006037A2 (es)
CR (1) CR20200212A (es)
CU (1) CU24701B1 (es)
EA (1) EA202090967A1 (es)
GE (1) GEP20237575B (es)
MX (1) MX2020004085A (es)
PE (1) PE20210106A1 (es)
PH (1) PH12020550266A1 (es)
SG (1) SG11202003408TA (es)
TW (1) TWI812650B (es)
UA (1) UA127829C2 (es)
WO (1) WO2019077622A1 (es)
ZA (1) ZA202002852B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4183411A1 (en) 2013-03-15 2023-05-24 Takeda Vaccines, Inc. Compositions and methods for dengue virus chimeric constructs in vaccines
CN117752780A (zh) 2017-12-07 2024-03-26 默沙东有限责任公司 登革病毒疫苗组合物的制剂
JP2023501693A (ja) * 2019-12-10 2023-01-18 レプリゲン・コーポレーション ウイルスベクターの調製方法
GB2600468A (en) * 2020-10-30 2022-05-04 Excivion Ltd Adjuvant composition
WO2023037387A2 (en) * 2021-09-08 2023-03-16 Serum Institute Of India Private Limited Freeze-dried viral combination vaccine compositions and process for preparation thereof
WO2023158989A1 (en) * 2022-02-15 2023-08-24 Takeda Vaccines, Inc. Dengue vaccine batch mixing process
WO2024086605A1 (en) * 2022-10-18 2024-04-25 Takeda Vaccines, Inc. Dengue vaccine formulation
WO2024118740A1 (en) * 2022-11-29 2024-06-06 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2829282B1 (en) * 2007-03-22 2017-10-25 The Regents of The University of Colorado, A Body Corporate Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
EP2143440A1 (fr) * 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
CN102215865B (zh) * 2008-09-24 2013-10-30 米迪缪尼有限公司 病毒纯化方法
US8795686B2 (en) 2008-11-07 2014-08-05 Serum Institute Of India Stable, dried rotavirus vaccine, compositions and process for preparation thereof
KR102023207B1 (ko) 2010-12-02 2019-11-25 온콜리틱스 바이오테크 인코포레이티드 동결건조 바이러스 제형
AU2013208187B2 (en) 2012-01-09 2018-07-12 Sanofi Pasteur Biologics, Llc Purification of flaviviruses
US10004795B2 (en) 2015-09-08 2018-06-26 Fundacao Butantan Process for preparing an attenuated tetravalent dengue vaccine
EP3355916A4 (en) 2015-09-30 2018-08-29 Panacea Biotec Limited Stable live attenuated recombinant dengue vaccine
US10751408B2 (en) * 2016-02-23 2020-08-25 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for making and using thermostable immunogenic formulations with increased compatibility of use as vaccines against one or more pathogens

Also Published As

Publication number Publication date
EP3697897A4 (en) 2022-02-23
AU2018352447A1 (en) 2020-06-11
KR20200088326A (ko) 2020-07-22
EA202090967A1 (ru) 2020-08-12
CN111655844A (zh) 2020-09-11
PE20210106A1 (es) 2021-01-19
JP2020537691A (ja) 2020-12-24
CO2020006037A2 (es) 2020-08-10
US11660333B2 (en) 2023-05-30
TWI812650B (zh) 2023-08-21
UA127829C2 (uk) 2024-01-17
CU20200036A7 (es) 2021-03-11
CA3079151A1 (en) 2019-04-25
TW201922272A (zh) 2019-06-16
PH12020550266A1 (en) 2021-03-01
SG11202003408TA (en) 2020-05-28
CN111655844B (zh) 2024-05-24
GEP20237575B (en) 2023-12-25
CR20200212A (es) 2020-07-17
EP3697897A1 (en) 2020-08-26
JP7261239B2 (ja) 2023-04-19
AR114138A1 (es) 2020-07-29
ZA202002852B (en) 2021-03-31
MX2020004085A (es) 2020-12-03
BR112020007513A2 (pt) 2020-10-06
WO2019077622A1 (en) 2019-04-25
US20210187092A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
CU24701B1 (es) Composiciones de vacuna estables que comprenden inter alia un flavivirus recombinante vivo atenuado y proceso para la preparación de las mismas
CO2019012893A2 (es) Composiciones farmacéuticas de atropina
EP4218807A3 (en) Zika virus vaccine
CO2017011245A2 (es) Conjugados proteína-polisacárido de estreptococo grupo b, métodos para producir conjugados, composiciones inmunógenas que comprenden conjugados y sus usos
BRPI0809663B8 (pt) composição de vírus vivo atenuado, usos da mesma, métodos de diminuição da inativação de vírus vivo atenuado, e kit para diminuir a inativação de uma composição de vírus vivo atenuado.
PE20150356A1 (es) Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue
WO2017156511A8 (en) Live attenuated zika virus vaccine
AR113257A1 (es) Virus chikungunya inmunogénico
PE20140646A1 (es) Vacuna de virus de dengue inactivado
PE20140871A1 (es) COMPOSICIONES Y METODOS DE VACUNA DEL VIRUS TIPO 1b DE DIARREA VIRAL BOVINA
EA201390812A1 (ru) Лиофилизированные вирусные составы
CO6470882A2 (es) Composiciones y metodos para administración de vacunas contra virus del dengue.
ECSP20007842A (es) Composiciones y métodos para formulaciones de alfavirus vivos atenuados
CU20180025A7 (es) Proceso de preparación de una vacuna tetravalente atenuada contra el virus del dengue
AR103427A1 (es) Vacuna contra la fiebre aftosa
GEP20237539B (en) Formulations of dengue virus vaccine compositions
AR101814A1 (es) Partícula de tipo virus flavivirus
CL2021003211A1 (es) Una cepa viva modificada, del virus del síndrome respiratorio y reproductivo porcino (prrs), vacuna que lo comprende y su uso para tratar el prrs tipo ii. (divisional solicitud no. 2123-2018)
CO2018010359A2 (es) Constructos de alfavirus vivo atenuado y métodos y usos de los mismos
BR112015031226A2 (pt) Composição de vacina, e, uso da composição de vacina
BR112023021812A2 (pt) Composição vacinal adjuvantada e métodos
UY35418A (es) Vacuna que proporciona protección frente a diferentes Picornavirus humanos.
MX2022010781A (es) Vacuna contra el virus sars-cov-2 con adyuvante cpg.
BR112016029201B8 (pt) Quimera de ácido nucleico, composição imunogênica, uso de um ou mais vírus inativados compreendendo a quimera de ácido nucleico e método para inativar um vírus
EA202090236A1 (ru) Иммуногенные композиции senecavirus a и способы с ними